Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy

Abstract Introduction Tafamidis is approved in many countries for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Approval is largely based on findings from an international phase 3 trial. This post-approval commitment study aimed to evaluate the safety and efficacy of...

Full description

Bibliographic Details

Published in:	Cardiology and Therapy
Main Authors:	Zhuang Tian, Daoquan Peng, Wei Ma, Jiangtao Yan, Jian’an Wang, Yida Tang, Wei Jin, Ying Liu, Caiping Jia, Yingxu Gao, Yankun Gong, Xiaohong Sun, Naihan Chen, Shuiqing Zhu, Shuyang Zhang
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-05-01
Subjects:	Heart failure Amyloidosis Quality of life Health status Functional status Adverse events
Online Access:	https://doi.org/10.1007/s40119-025-00408-6